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1. Introduction  
Myasthenic crisis is a life-threatening complication of myasthenia gravis (MG) that is 
traditionally defined as weakness of respiratory muscles that is severe enough to require 
intubation or artificial respiratory support (Jaretzki et al., 2000). Rapid and marked 
increase in limb and bulbar weakness without respiratory failure, however, should 
probably be also defined as crisis in a myasthenic patient. Although it is potentially life-
threatening, the mortality rate has declined dramatically with better and more aggressive 
care in the intensive care unit (ICU) and the widespread use of immunotherapies (Varelas 
et al., 2002; Thomas et al., 1997). Respiratory management of these patients, however, is 
very challenging due to the fluctuating nature of the disease. Assiduous attention to 
respiratory care provides support of the patient, allowing time for therapy of the 
underlying myasthenia to be effective. There are deficiencies in current services for 
myasthenic crisis in that the ICU physicians not being expert respiratory specialists, and 
physicians managing mechanical ventilation not experienced in neurologic aspects of 
these patients.  
This chapter reviews the respiratory dysfunction in myasthenic crisis and discusses issues 
related to respiratory care in these patients, including airway management, mechanical 
ventilation and extubation outcome.  
2. Epidemiology 
Myasthenic crisis occurs in 15 to 20% of patients with MG during their lifetime 
(Phillips, 2004 ). It usually occurs during the course of first symptomatic presentation in the 
young and later in the course of the disease in the elderly. The median time to first 
myasthenic crisis from onset of MG ranges from 8 to 12 months (Thomas et al., 1997; 
Rabinstein et al., 2005). However, crisis may be the initial presentation of MG in one-fifth of 
patients (Rabinstein et al., 2005;. O’Riordan et al., 1998). Overall, women are twice as likely 
as men to be affected. There is a bimodal distribution of myasthenic crisis, with an early 
peak prior to age 55 affecting women 4:1, whereas a later peak after age 55 affecting women 
and men equally (Thomas et al., 1997). The average age of admission with crisis is 59 years 
(Wendell et al., 2011). Pregnancy is associated with an aggravation of myasthenia gravis in 
approximately a third of all women and myasthenic crisis in pregnancy carries high 
perinatal mortality (Plauche, 1991). 
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The incidence of crisis remains stable from 1960s to 1990s (Cohen and Younger, 1981). 
Recently, an increasing incidence of MG, especially in the elderly population, has been 
observed in some countries (Pakzad, 2011), and the incidence of anti-acetylcholine receptor 
(AChR) seropositivity in the ≥ 65 age group has increased at a significantly greater rate than 
the rate of increase in the younger people. It is very rare for patients with myasthenia to 
need long-term invasive or noninvasive ventilator support, although that need is slightly 
more common in patients with muscle specific tyrosine kinase (MuSK) antibodies (MuSK-
MG) as opposed to AChR antibodies (AChR-MG). 
3. Precipitants of myasthenic crisis 
Myasthenic crisis may be precipitated by a variety of factors, most often a concurrent 
infection (Mayer, 1997; Wendell and Levine, 2011’ Thomas et al., 1997). Although patients 
with MG can develop any common infection that can result in decompensation, the most 
likely source of infection is pulmonary. One series documented infection in 38% of patients 
presenting with myasthenic crisis. The most common cause was bacterial pneumonia, 
followed by a bacterial or viral upper respiratory infection (Thomas et al., 1997). Other 
precipitants can be surgery, menstruation, pregnancy, childbirth, or tapering of 
immunosuppressive medications, exposure to temperature extremes, pain, sleep 
deprivation, and physical or emotional stress. The precipitant may not be found in up to 
one-third of cases (Mayer, 1997; Thomas et al., 1997; O’Riordan et al., 1998). In addition, 
crisis can occur spontaneously as part of the natural history of MG itself (Thomas et al., 
1997; O’Riordan et al., 1998; Juel, 2004). A number of drugs can increase the weakness in 
myasthenia and should be considered as possible precipitants in this setting. This is of more 
concern with certain antibiotics (aminoglycosides, erythromycin and azithromycin), cardiac 
drugs (β-blockers, procainamide, and quinidine), and magnesium (Wendell and Levine, 
2011). Although corticosteroids can be used in the treatment of MG, initial treatment with 
prednisone led to an exacerbation of MG in almost half of patients in 1 series (Pascuzzi et al., 
1984). The incidence of myasthenic crisis resulting from corticosteroids ranges from 9 to 18% 
(Pascuzzi et al.,1984; Bae et al., 2006). Therefore, initiation of corticosteroid therapy for the 
treatment of MG should always occur in a hospital setting, where respiratory function can 
be monitored (Pascuzzi et al, 1984). Predictors of exacerbation from prednisone include 
older age, lower score on the Myasthenia Severity Scale, and bulbar symptoms (Bae et al., 
2006).  
4. Pathophysiology and clinical presentations 
The respiratory failure in myasthenic crisis can be of either the hypoxemic or the 
hypercapnic form, and may result from the combination of poor airway protection, 
inadequate secretion clearance and hypoventilation (Juel, 2004; Borel et al., 1993; Mier-
Jedrzejowicz et al., 1988). Muscle weakness in AchR-MG tends to initially affect the 
intercostal and accessory muscles and then the diaphragm (Chaudhuri and Behan, 2009). 
Bulbar (oropharyngeal) muscle dysfunction may be the predominant feature in some 
patients (Putman and Wise, 1996). In MuSK-MG, bulbar weakness always precedes 
respiratory failure (Chaudhuri and Behan, 2009). The central ventilatory drive in 
myasthenics usually remains intact during crisis, even when the minute ventilation response 
to CO2 is poor (Rabinstein and Wijdicks, 2003).  
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Clinically, ptosis, ophthalmoparesis, and facial and bulbar weakness are common, in 
addition to generalized weakness. At the bedside, recruitment of accessory muscles 
indicates significant inspiratory muscle weakness, and a weak cough or difficulty in 
counting to 20 in a single breath signifies weakness of the expiratory muscles (Juel, 2004). 
Patient anxiety, accompanied by tachycardia and tachypnea, may be the first sign of air 
hunger (Table 1). Signs of bulbar weakness include dysphagia, nasal regurgitation, a nasal 
quality to speech, staccato speech, jaw weakness (jaw closure weaker than jaw opening), 
bifacial paresis, and tongue weakness (Garcia-Pachon et al., 1996; Rabinstein and Wijdicks, 
2003). The most important dysfunction of the upper airway leading to respiratory failure is 
laryngeal muscle weakness causing abnormal adduction of the vocal cords during 
inspiration and even paralysis (Friedman and Goffin, 1966). Respiratory failure may develop 
due to aspiration, catastrophic airway compromise, or increased work of already fatigued 
respiratory muscles against a closed airway (Putman and Wand, 1996). 
One particular danger in myasthenic crisis is that the generalized weakness can mask the 
usual signs of respiratory distress. In addition, weak respiratory muscles may suddenly 
fatigue, producing precipitous respiratory collapse. Some patients may present with 
respiratory insufficiency out of proportion to limb or bulbar weakness. In rare cases of 
myasthenic crisis, ventilatory failure is the only clinically overt manifestation (Mier et al., 
1990; Dushay et al., 1990). Therefore, signs of myasthenic crisis should be sought in all 
patients with MG, even when they do not complain of weakness.  
 
Abdominal muscle paradox 
Accessory muscle use 
Cough after swallowing 
Difficulty in clearing secretions 
Dysphagia 
Hypophonia 
Inability to raise the head due to neck muscle weakness 
Forehead sweating 
Jaw weakness (jaw closure weaker than jaw opening) 
Nasal regurgitation  
Orthopnea 
Pausing during speech to take a breath 
Rapid shallow breathing 
Staccato speech or a nasal quality to speech 




Weak cough  
Wet, gurgling voice 
Table 1. Warning symptoms and signs of impending respiratory failure in myasthenic crisis.  
(Rabinstein, 2003; Bedlack and Sanders, 2002; Juel, 2004) 
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5. Assessment of respiratory muscle strength and bulbar function  
5.1 Assessment of vital capacity (VC)  
The VC reflects the mechanical function of both inspiratory and expiratory respiratory 
muscles and can be performed at the bedside to assess the patient's trend (Juel, 2004; 
Rabinstein and Wijdicks, 2003). The patient is instructed to take a deep breath in and then to 
exhale maximally into a spirometer. Some experts recommend assessing both supine and 
sitting VC, as diaphragmatic weakness is more apparent on the supine measurement. 
Supine VC has been shown to be an earlier marker of detect diaphragm dysfunction. 
5.2 Assessment of inspiratory muscle function 
5.2.1 Maximal inspiratory pressure (PImax) 
The static PImax measured during a maximal inspiratory effort that is sustained for ≥ 1 s 
against an occluded airway is the most widely used parameter for assessing inspiratory 
muscle strength, Although the early literature reported that PImax testing should be 
performed from residual volume (RV), more recent work has shown that it is reasonable to 
simplify the procedure by measuring this pressure from the functional residual capacity (FRC) 
(Windisch et al., 2004). The normal range of PImax values is wide and some patients may have 
difficulties in performing the procedure, particularly those with bulbar dysfunction. 
5.2.2 Sniff nasal inspiratory pressure (SNIP) 
Alternative techniques have been developed over the last few years to assess the inspiratory 
function. One of the most promising is determination of SNIP, which consists in the 
measurement of pressure through an occluded nostril during sniffs, performed through the 
contralateral nostril (Soliman et al., 2005). The testing of SNIP should be performed from FRC. 
It has been shown to be a good physiological marker of inspiratory muscle strength (Martínez-
Llorens et al., 2011). SNIP maneuver is easier to perform than PImax maneuver, and it is as 
reproducible as Pimax, However SNIP may underestimate esophageal pressure swing in 
subjects with nasal obstruction and severe neuromuscular weakness. Multiple tests to assess 
respiratory muscle strength are required to exclude weakness in symptomatic patients (Steier 
et al, 2007; Hart et al., 2003). Because, of the limit of agreement between SNIP and PImax, these 
two methods are not interchangeable but complementary (Prigent et al., 2004). 
5.2.3 Sensitivity of volume vs. pressure measures 
It remains controversial whether volume or pressure measurements are more sensitive in 
the assessment of respiratory muscle function. The theoretical curvilinear relation between 
volume and pressure implies that, in the case of mild respiratory muscle weakness, VC is 
less sensitive than PImax, and, in more advanced disease, marked reduction in VC can occur 
with relatively small changes in maximum pressures. One previous study showed that 
inspiratory and expiratory forces were more sensitive than VC in evaluating muscle 
strength in MG (Mier-Jedrzejowicz et al., 1988). However, a recent study found that PImax 
was not more sensitive than VC for early detection of respiratory muscle failure in these 
patients (Prigent et al., 2011). Since neither measurement has been shown to be superior, the 
two parameters are usually analyzed in combination. 
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5.3 Assessment of expiratory muscle function 
5.3.1 Maximal expiratory pressure (PEmax) 
The strength of the expiratory muscles can be assessed by the maximal expiratory pressure 
(PEmax) (Rabinstein et al., 2003), which can be measured at the mouth in an analogous 
fashion to PImax during a forced expiration (from total lung capacity maneuver). It 
represents the integration of exhalation muscle strength and sufficient cough flows have to 
be generated by expiratory muscles to allow airway clearance. In a study of neuromuscular 
diseases (Perez, 2006), PEmax below 45 cm H2O was associated with compromised cough 
efficiency, and PEmax < 40 cm H2O may indicate crisis (Lacomis, 2005). It is important to 
prevent the subject from using buccal manoeuvres to increase the mouth pressure. As with 
PImax, PEmax values have a wide normal range.     
5.3.2 Peak cough flow 
Another simple and commonly used test of expiratory muscles is the peak cough flow, 
which can be performed using a standard peak flow meter attached to a face mask and 
usually requires little or no coaching to produce acceptable technique. Cough assessment is 
an inexact science, however, because of the lack of accurate measures. A peak cough flow 
value of < 270 L/min has been proposed as a threshold for cough inadequacy, but this has 
never been validated. Patients with a peak cough flow < 180 L/min are unable to 
independently clear secretions (Bach, 1995). In myasthenics, peak cough flow has been 
shown to be useful in monitoring expiratory muscle strength (Suárez et al., 2002; Wilson et 
al., 2005). It must be realized that although this test indicates expiratory muscle performance 
the pressure and force generated depends on lung volumes and coordinated bulbar function 
to rapidly open and close the glottis during cough pressure generation and release. 
Therefore, values obtained will be reduced in patients with inspiratory muscle weakness 
due to inability to perform deep inspiration prior to cough initiation (Polkey et al., 1998).  
5.4 Assessment of bulbar function 
Although critical for management decisions, reliable clinical assessment of bulbar function 
with MG is often difficult (Hudspeth et al., 2006). As it is well established, the involvement 
of upper airway muscles in neuromuscular diseases can produce abnormalities of the 
maximum flow-volume loop (MFVL) in the form of upper airway obstruction and/or flow 
oscillations (Putman and Wise, 1996). Upper airway obstruction is much more common in 
patients with MG than previously recognized. In one study, 7 of the 12 MG patients 
examined disclosed a pattern of extrathoracic upper airway obstruction (Putman and Wise, 
1996). In addition, a crude but effective bedside test can be performed by asking the patient 
to sip water and then observing for coughing or choking. This “slurp” test has been shown 
to be valuable for identifying serious compromise of bulbar function and for monitoring and 
guiding therapy in pediatric patients with MG (Hudspeth et al., 2006). 
6. Initial respiratory care in the ICU 
The respiratory management of myasthenic crisis does not differ between patients with 
AChR-MG, MuSK-MG and seronegative patients (Chaudhuri and Behan, 2009).  
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6.1 Initial evaluation and airway management 
Patients with crisis should be referred for intensive care. The initial step is stabilization of 
the airway. The airway should be opened by suctioning secretions after positioning the jaw 
and tongue. High-flow oxygen should be administered and oxygen saturation be monitored 
by pulse oximetry continuously. If respirations remain inadequate, patients can be 
ventilated by a bag-valve mask while preparing to intubate. In the patient without an intact 
gag reflex, an oral airway may be placed to prevent aspiration. Patients should always be 
asked about recent difficulty with swallowing, choking, coughing after eating, and nasal 
regurgitation. If the patient’s history or the “slurp” test is suggestive of dysphagia, oral 
intake is eliminated. 
Once the airway is secured, investigation into the cause of the exacerbation of MG may 
proceed. Any medication suspected of precipitating crisis should be discontinued (Keesey, 
2004). Chest radiography is important in detecting pneumonia. Appropriate broad-spectrum 
antibiotics are indicated for sepsis and pneumonia. It is important to consider that 
fluoroquinolones and aminoglycosides may adversely affect muscle function in these 
patients, and these antibiotics should be avoided if possible.  
Prompt recognition of impending respiratory paralysis is the key to successful management. 
The classical signs of respiratory distress, however, often occur too late in these patients to 
serve as guidelines for management. Respiratory assistance should be provided if VC is < 
15-20 mL/kg, the tidal volume < 5–6 mL/kg, or if PaO2 drops to < 85 mm Hg and PaCO2 
increases to > 45 mm Hg. Oxygen saturation and ABG abnormalities, however, are generally 
not considered ideal for use in making intubation decisions because these values change late 
in the decompensation cycle (Juel, 2004; Rabinstein and Wijdicks, 2003; Bird and Teener, 
2001). 
6.2 Bronchodilator therapy 
One recent study found that patients with MG had significantly lower FEV1/FVC ratio than 
controls. This was more marked in patients on acetylcholine esterase inhibitors (Elsais et al., 
2010). In myasthenic crisis, bronchodilators may be useful in maintaining airway patency 
and overcoming bronchospasm. For myasthenics with concomitant chronic obstructive 
pulmonary disease (COPD), inhaled ipratropium bromide may be the bronchodilator drug 
of choice because it is safe and can decreased bronchial secretions which may limit the use 
of cholinesterase inhibitors (Szathmáry et al., 1981; Liggett et al., 1988). A recent pilot study 
also suggests that terbutaline, a β2 adrenergic agonist, may be an effective adjunct therapy in 
these patients, although confirmation with larger trials will be required (Soliven et al., 2011).  
6.3 Indications and predictors for endotracheal intubation 
Two-thirds to 90% of patients with myasthenic crisis require intubation and mechanical 
ventilation (Thomas et al., 1997; O’Riordan et al., 1998). Over 20% of patients require 
intubation during evaluation in the emergency department, and almost 60% are intubated 
after admission to an ICU (Thomas et al., 1997). The absolute indications for intubation may 
include cardiac or respiratory arrest, impaired consciousness shock, life-threatening 
arrhythmias, severe blood–gas alterations, and bulbar dysfunction with confirmed aspiration. 
Much more difficult is the decision to intubate when such strict criteria are not met.  
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In most patients, repeated measurements of VC and PImax help determine the need for and 
timing of elective intubation (Ahmed et al., 2005; Rabinstein and Wijdicks, 2003). These 
indices can be measured as often as every two hours, but typically every four hours. The 
standard 20/30/40 rule (VC < 20 mL/kg; PImax <_30 cm H2O and PEmax < 40 cm H2O) is 
probably the most helpful guide to decide when intubation (Chaudhuri and Behan, 2009). 
However, these threshold values have not been established through prospective studies, nor 
do they allow for individual differences in size, sex, and age. In addition, muscle weakness 
in myasthenic crisis often fluctuates, and patients can develop apnea very suddenly, or may 
precipitously fatigue with the rapid development of respiratory failure before a downward 
trend in these parameters is noted. Facial weakness can also lead to inaccurate 
measurements of these indices due to inability to make a good seal with the mask (Lacomis, 
2005). In a retrospective review, repeated measurement of VC did not predict the need for 
intubation and mechanical ventilation in these patients (Rieder et al., 1995). Thus, these 
respiratory parameters should always be interpreted in the context of the clinical symptoms 
and signs, as well as the trend in these measures. Regardless of respiratory function indices, 
the need for mechanical ventilation is a sufficient criterion to define myasthenic crisis 
(Ahmed et al., 2005). With close monitoring of the patient's condition, endotracheal 
intubation can often be performed electively rather than as an emergent response to 
precipitous respiratory collapse (Juel, 2004; Rabinstein and Wijdicks, 2003; Bird and Teener, 
2001).  
6.4 Procedures for endotracheal intubation 
Should the need for emergent intubation develop, rapid sequence intubation should be 
modified because neuromuscular blocking agents (paralytics) should be used with caution 
when intubating these patients. Depolarizing agents (for example, succinylcholine) are less 
potent in myasthenics because fewer functional post-synaptic anti-AChR are available. This 
decrease in receptors also results in a decrease in the safety margin or remaining AChR 
available for neuromuscular transmission. Nondepolarizing agents (fornexample, 
vecuronium) have increased potency, and reduced doses are required for paralysis. (Baraka, 
1992). A rapid-onset nondepolarizing agent (ie, rocuronium, vecuronium) is the preferred 
paralytic agent for these patients. Although nondepolarizing agents delay the onset of 
paralysis, compared with succinylcholine, these medications do not result in unwanted 
prolonged paralysis. Following paralysis, intubation is accomplished as usual. A soft, low-
pressure cuff is recommended. After intubation, chest radiography should be taken to 
confirm the position of the artificial airway. 
6.5 Modification of pharmacotherapy after intubation 
After intubation, cholinesterase inhibitor therapy is usually temporarily withdrawn to avoid 
the excess secretions that may complicate pulmonary management. In addition, continued 
use of these medications confounds the assessment of other treatment modalities and can 
increase muscle weakness if used in excess (Ahmed et al., 2005). These medications do not 
alter the course of the crisis and offer solely symptomatic relief of MG (Juel, 2004). After 
patients have shown definitive improvement in muscle strength, usually several days after 
the initiation of intravenous immunoglobulin (IVIg) or plasma exchange, 
acetylcholinesterase inhibitors, typically oral pyridostigmine, can be reintroduced after or 
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just prior to extubation (Juel, 2004; Ahmed et al., 2005). Oral pyridostigmine is preferred, but 
it may be given intravenously. One milligram of intravenous pyridstigmine is equal to 30 
mg of oral pyridostigmine. Patients should be started on a low dose of the medication that is 
titrated to symptomatic relief (Ahmed et al., 2005). Continuous intravenous infusion of 
pyridostigmine as treatment for myasthenic crisis may have efficacy similar to that of 
plasma exchange, but it is associated with an increased risk of life-threatening cardiac 
arrhythmia (Wendell and Levine, 2011). Unless contraindicated, all patients should be 
treated with low molecular weight heparin to prevent deep vein thrombosis and pulmonary 
embolism (Chaudhuri and Behan, 2009).  
7. Ventilatory management strategies 
7.1 Ventilator settings   
Once intubated, patients should be placed in a semi-recumbent position with the head of the 
bed at approximately 30 degrees. Large tidal volumes of 10 mL/kg, along with pressure 
support of 5 to 15 cm H2O and positive end-expiratory pressure (PEEP) of 5 to 15 cm H2O, are 
encouraged to limit atelectasis, provided peak airway pressures can be maintained below 40 
cm H2O (Kirmani et al., 2004; Varelas et al., 2002). The degree of support required is patient-
dependent and should be adjusted based on ABG analysis. In patients with chronic carbon 
dioxide retention (suggested by elevated serum bicarbonate levels), PaCO2 should be kept 
above 45 mm Hg to avoid alkalosis and bicarbonate wasting, which make weaning more 
difficult. Frequent checks of cuff pressure, tube placement, and blood gases are recommended. 
7.2 Chest physiotherapy and airway clearance  
Meticulous attention to pulmonary toilet is required because of an ineffective cough 
mechanism. Aggressive chest physiotherapy and airway clearance should be implemented 
(Varelas et al., 2002). Inspired gas humidity should be around 80% at 37°C. Various 
modalities, include percussion, vibration, and postural drainage. should be carried out to 
loosen and remove bronchial secretions and to achieve better aeration of collapsed areas of 
the lung (Brooks-Brunn, 1995; Lewis, 1980; Selsby and Jones, 1990). Regular suctioning 
serves to not only remove excess oropharyngeal and tracheal secretions but also to stimulate 
coughing (Varelas et al., 2002). Patients with a cough PEF < 180 L/min can augment cough 
response with manual physiotherapy and using insufflation-exsufflation devices (Chatwin 
et al., 2003) and this augmented cough level is associated with improved prognosis 
independent of VC or breathing pattern (Bach, 1995).  
If atelectasis is severe and does not respond to routine measures, therapeutic fiberoptic 
bronchoscopy can be performed to promote airway toilet. Frequent body repositioning is 
effective in enhancing oxygen transport by changing the ventilation and perfusion of the 
lungs through gravitational effects and by enhancing mobilization of secretions. Early 
mobilization and ambulation as tolerated is also encouraged.  
7.3 Nutrition and other issues during mechanical ventilation 
Adequate nutrition is important to avoid a negative energy balance and worsening of 
muscle strength (Kirmani et al., 2004). All patients received adequate nutritional support 
(25–35 calories per kilogram) via enteral route whenever possible. In patients with 
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hypercarbia and difficulty weaning from the ventilator, low carbohydrate feeds are the 
preferred solution (Varelas et al., 2002). 
In addition to the aforementioned measures, abnormal laboratory values that could affect 
muscle strength should also be corrected. Potassium, magnesium, and phosphate depletion 
can all exacerbate myasthenic crisis and should be repleted. Anemia can also increase 
weakness, and several experts recommend transfusions when hematocrit values are under 
30% (Kirmani et al., 2004; Ahmed et al., 2005). Prophylaxis for deep vein thromboses, such 
as administration of subcutaneous heparin sodium or use of pneumatic compression boots, 
is recommended. 
8. Weaning from mechanical ventilation and risks for extubation failure 
8.1 Disadvantages of prolonged intubation  
Prolonged intubation in myasthenic patients may lead to several complications such as 
atelectasis, anemia, urinary tract infection, congestive heart failure (Ahmed et al., 2005), and 
ventilator-associated pneumonia (VAP) (Wu et al., 2008). Patients with a prolonged 
intubation were hospitalized 3 times longer and were less likely to be functionally 
independent upon discharge (Thomas et al., 1997). In one series, 3 independent risk factors 
for prolonged intubation (>14 days) were identified: age > 50 years, peak VC < 25 mL/kg on 
post-intubation days 1 to 6, and a serum bicarbonate ≥ 30 mmol/L (Thomas et al., 1997). All 
of the patients with no risk factors were intubated for less than 2 weeks, whereas 88% of the 
patients with all 3 risk factors had prolonged intubation.   
8.2 Evaluation for weaning in myasthenia crisis    
Deciding on when to stop mechanical ventilation in myasthenic crisis is a challenge for the 
intensivists, because the usual criteria don’t necessarily apply. Evaluation for weaning 
should begin when patients are objectively getting stronger on examination. In addition, 
improvement in the strength of neck flexors and other adjunct muscles is usually associated 
with improvement in bulbar and respiratory muscle strength and can be a useful tool for 
assessing clinical improvement (Meriggioli, 2009). Patients should be transitioned to a 
spontaneous mode of ventilation (eg, pressure support ventilation) in which all breaths are 
patient initiated. Pressure support can then gradually be decreased to minimal settings, 
usually 5 to 8 cm H2O. If results of assessments indicate muscle fatigue, the previous level of 
ventilator support should be reinstituted (Kirmani et al., 2004). In patients with chronic CO2 
retention, PaCO2 should be kept above 45 mm Hg to avoid alkalosis and bicarbonate 
wasting, which may make weaning more difficult. 
Current recommendations about managing the weaning process emphasize the daily 
determination of simple criteria (Fly et al., 1996; Fly et al., 1999). Some criteria are generally 
used: 1) Satisfactory oxygenation, for instance PaO2/FIO2 ≥ 200 mm Hg with PEEP ≤_5 cm 
H2O; 2) A criterion for hemodynamic stability, e.g., no continuous vasopressor infusion; 3) 
Patient awake or easily aroused and sedation stopped; and 4) Patient able to cough effectively. 
8.3 Spontaneous breathing trial (SBT) 
Readiness for extubation from a respiratory standpoint is largely judged on the basis of 
patient performance during an SBT. Two main methods are used: T-piece and a low level of 
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PSV, with a duration ranging from 30 min to 2 hours (Esteban et al., 1997). It should always 
begin early in the day. During this period, patient anxiety, pulse and respiratory rates, and 
tidal volume again are frequently documented. There are no good clinical criteria for when 
and how to try extubation safely, thus avoiding the need for reintubation. Fluctuating 
weakness and pulmonary complications often confound the decision to extubate 
(Seneviratne et al., 2008). Patients are typically extubated if VC and PImax are ≥ 15 mL/kg 
and ≤_- 20 cm H2O, respectively, and tidal volume ≥ 5 mL/kg (Kirmani et al., 2004; 
Meriggioli, 2009). In our study, a PEmax of > 40 cm H2O was a good predictor of extubation 
success in these patients (Wu et al., 2009). If the patient complains of fatigue or shortness of 
breath, extubation should not be performed even if the criteria of these indices are met and 
blood gases are normal (Berrouschot et al., 1997; Gracey et al., 1983; Kelly, 1991). Our 
experience also indicates that the rapid shallow breathing index (breathing frequency 
divided by tidal volume) is a poor predictor for extubation outcome in patients with 
neuromuscular diseases (Kuo et al., 1996; Wu et al, 2009).  
8.4 Potential utility of new modes of mechanical ventilation  
Some new modes of mechanical ventilation, which are aimed at unloading the inspiratory 
muscles and preventing patient-ventilator dyssynchrony, may be useful in neuromuscular 
patients with difficult weaning. These modes include proportional assist ventilation (PAV), 
adaptive support ventilation (ASV), and neurally-adjusted ventilatory assist (NAVA). 
However, there is still no evidence from randomized controlled trials to support or refute 
the use of these modes in myasthenic crisis. Automatic tube compensation (ATC) is a special 
mode of ventilatory support which delivers the amount of pressure necessary to overcome 
the resistive load imposed by the endotracheal tube for the flow measured at the time (Fabry 
et al., 1994). This mode therefore unloads the flow-resistive properties of the artificial airway 
and can increase the probability of successful extubation. One recent report indicates that 
the addition of ATC to a standard PSV-based weaning protocol significantly shortened time 
needed to wean patients with severe neuromuscular paralysis (Agarwal et al., 2009). It is 
possible that ATC will be a useful weaning mode in myasthenic crisis, especially for patients 
who are intubated with a small-size endotrachel tube.      
8.5 Respiratory care after extubation  
To enhance mucous clearance and prevent sputum impaction after extubation, it is 
reasonable to consider airway clearance techniques, such as positive expiratory pressure, 
autogenic drainage, and active cycle of breathing techniques in these patients (Hardy and 
Anderson, 1996). The addition of mechanical insufflation/exsufflation may shorten airway-
clearance sessions in neuromuscular patients with chest infection (Chatwin and Simonds, 
2009). The intrapulmonary percussive ventilator and high-frequency chest wall oscillator 
with vests may show growing promise in this area (Toussaint et al., 2003). However, these 
modalities have not been specifically in myasthenics. Externally applied pressure, such as 
with the In-Exsufflator or the cyclically inflated pneumatic belt, can augment the patient's 
own efforts and is sometimes helpful. Normalizing the VC and FRC typically helps to 
improve the ability to cough and clear secretions. Sputum mobilization can be facilitated 
with the Flutter valve therapy without the assistance of another caregiver, as long as the 
patient has the motivation. Incentive spirometry can also be used to reduce the risk of 
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atelectasis and re-intubation (American Association for Respiratory Care, 1991), but its 
usefulness in myasthenic crisis patients is not clear. 
The risk of spontaneous relapse of myasthenic crisis is low in early-onset disease. A third of 
late onset severe disease, especially in MuSK-MG, may experience recurrent crisis 
(Chaudhuri and Behan, 2009). Therefore, close observation for 72 hours in the ICU is 
recommended for each patients after extubation. The duration of observation may have to 
be longer for less stable patients. 
8.6 Extubation outcome and the risk of extubation failure 
The rate of extubation failure in medical patients undergoing invasive mechanical 
ventilation ranges from 3% to 19% (Epstein et al., 1997; Mador,  1998). This percentage seems 
to be much higher in neuromuscular diseases. One study published in 1997 reported that 
only half of patients were extubated within two weeks after intubation (Thomas et al., 1997). 
More recent studies indicate that extubation failure still occurs in more than 25% of these 
patients (Rabinstein and Mueller-Kronast, 2005; Seneviratne et al., 2008). Reintubaton is a 
significant event because these patients have significantly longer ICU and hospital stays 
(Rabinstein and Mueller-Kronast, 2005). Extubation failure is also associated with a higher 
incidence of ventilator-associated pneumonia (VAP) (Wu et al., 2009). Atelectasis is the most 
important risk factor for extubation failure in myasthenic crisis. Two retrospective studies 
found atelectasis in all patients requiring reintubation (Rabinstein and Mueller-Kronast, 
2005; Seneviratne et al., 2008). Other factors identified include older age, pneumonia, 
acidosis, decreased VC, and need for noninvasive ventilatory support are predictors of 
reintubation (Rabinstein and Mueller-Kronast, 2005; Seneviratne et al., 2008; Wu et al., 2008).  
Cough power is a strong predictor for extubation success in neuromusclar diseases. Bach 
and Saporito have reported that all patients with a cough PEF < 160 L/min had to be 
reintubated within 48 hours, the most likely reason being airway congestion because of the 
lack of adequate cough assistance (Bach and Saporito, 1996). In addition, patients who had 
passed SBT but presented cough PEF of 60 L/min or less were nearly 5 times more likely to 
fail extubation compared with those with cough PEF higher than 60 L/min (Salam et al., 
2004). In myasthenics, our data indicate that extubation failure is most commonly associated 
with a weak cough and inadequate airway clearance, and Pemax is useful in predicting 
cough strength after extubation (Wu et al., 2009). 
8.7 Tracheostomy  
Tracheostomy is generally not needed in myasthenic crisis because the duration of 
intubation is often less than 2 weeks. Tracheostomy placement ranges from 14 to 40% 
(Thomas et al., 1997; Rabinstein and Mueller-Kronast, 2005). In our retrospective analysis of 
41 episodes, tracheostomy was performed in four (9.8 %) patients after being ventilated for a 
median duration of 26 days (range: 20 to 30 days) (Wu et al., 2009). All these four patients 
were finally liberated from mechanical ventilation (Wu et al., 2009). One rare condition in 
myasthenic crisis that often requires tracheostomy is severe upper airway obstruction due to 
bilateral vocal cord paralysis. Approximately 11 such cases have been been reported in the 
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9. Role of non-invasive positive pressure ventilation (NIPPV) 
9.1 Advantages of NIPPV in neuromuscular diseases 
The application of NIPPV can augment airflow and prevents airway collapse and 
maintaining gas exchange by offering positive airway pressure both in the inhalation and 
exhalation phases of respiration. It has been applied successfully in slowly progressive 
neuromuscular diseases, such as Duchenne muscular dystrophy or amyotrophic lateral 
sclerosis (Seneviratne et al., 2008). NIPPV should be started at low pressures initially and 
then inspiratory pressure is gradually increased while monitoring tolerance, symptoms, and 
gas exchange. NIPPV is also increasingly being used to prevent extubation failure in these 
patients. A recent prospective study suggests that application of NIPPV, combined with 
assisted coughing after extubation, averts the need for reintubation or tracheostomy in 
patients with neuromuscular diseases and shortening their stay in the ICU (Vianello et al., 
2011). It should be included in the routine approach to these patients at high risk for 
postextubation respiratory failure. 
9.2 Contraindications and disadvantages of NIPPV 
Contraindications remain to the application of NIPPV in the acute setting, including 
respiratory arrest, severe inability to protect the airway, uncontrollable airway secretions 
despite use of noninvasive aids, life-threatening hypoxemia, severely impaired mental 
status or agitation, hemodynamic or electrocardiographic instability, and bowel obstruction 
(Hill et al., 2011). In patients with bulbar involvement, air blowing through a mask can lead 
to aspirated secretions and great care must be taken when using this modality (Wu et al., 
2009). Current evidence suggests that NIPPV should be used judiciously, if at all, in patients 
with postextubation respiratory failure (Aqarwal et al., 2007). 
9.3 Application of NIPPV in myasthenic crisis   
The definition of myasthenic crisis was introduced before NIPPV was widely applied to 
patients with hypercapnic respiratory failure. One common dilemma is whether to do 
immediate intubation in a patient presenting with warning signs of imminent respiratory 
failure or to start with NIPPV support. There are studies that lend some credence to its use 
in selected patients with myasthenic crisis. In 2002, Rabinstein et al. first reported their 
experience of using NIPPV in these patients. In their case series, NIPPV was well tolerated 
and the length of hospital stay was significantly reduced compared to those who were 
intubated (mean 7 ± 5 days vs. 23 ± 16 days; p = 0.03). Most failures (75%) occurred within 
the first 24 hours of NIPPV use (Rabinstein et al., 2002). Several subsequent reports suggest 
that NIPPV may be useful in preventing intubation as well as reintubation in these patients 
(Rabinstein and Wijdicks, 2002; Rabinstein and Wijdicks, 2003; Seneviratne et al., 2008; Wu 
et al., 2009). In 60 episodes of crisis in 52 patients, Seneviratne et al. reported that NIPPV 
was the initial method of ventilatory support in 24 episodes, and intubation was avoided in 
14 of these episodes (Seneviratne et al., 2008). Patients treated initially with NIPPV require 
ventilatory support for a median of 4 days versus 9 days in those patients initially intubated. 
A recent report also indicate that patients undergoing NIPPV spend one-third less time in 
the ICU and in the hospital, and the predictor of NIPPV failure was a PaCO2 level exceeding 
45 mm Hg on NIPPV initiation (Seneviratne et al., 2008). One retrospective cohort study 
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found that NIPPV was never aborted because of excessive respiratory secretions in 
myasthenics, and there was no difference in pulmonary complications between those 
supported with NIPPV and those supported with endotracheal intubation mechanical 
ventilation (Seneviratne et al., 2008). In our study, independent predictors of NIPPV success 
were a serum bicarbonate < 30 mmol/L and an APACHE (Acute Physiological And Chronic 
Health Evaluation) II score < 6 (Wu et al., 2009). Our experience also suggests that 
intubation should be performed if the patient on NIPPV has continued or worsening 
shortness of breath, tachypnea, or hypercapniea.  
9.4 NIPPV to prevent reintubation 
Early application of NIPPV after extubation can reduce the risk of respiratory failure and 
lowered mortality in hypercapnic patients with chronic respiratory disorders (Ferrer et al., 
2009). Use of NIPPV to avoid reintubation in myasthenic crisis is well established but 
relatively uncommon practice (Saeed and Patel, 2011). Some studies reported that NIPPV 
prevented reintubation in 70% of patients (Wu et al., 2009; Rabinstein and Wijdicks, 2002). 
Randomized controlled trials on the technique should be conducted before concluding the 
overall beneficial outcome.  
10. Role of negative pressure ventilation  
In recent years, the development of more portable and flexible devices has resulted in the 
renewed interest in the use of negative pressure ventilation to minimise the complications 
associated with positive pressure ventilation. Many of these devices can make the patients 
more comfortable with the ability to talk, eat and breathe freely around the mandatory 
negative pressure breaths. For example, the latest generation of biphasic cuirass ventilators 
are versatile and the duration and pressure can be altered in both the inspiratory and 
expiratory phases, which can promote the removal of secretions by external high-frequency 
oscillation as well as expiratory (cough) assistance (Linton, 2005; Koto et al., 2009). For 
myasthenic patients with relatively normal pulmonary compliance and airway resistance, it 
makes good sense to try cuirass ventilation to achieve earlier extubation. It should also 
reduce the incidence of VAP and laryngeal injury. Patients can then be moved to a step 
down or intermediate care facility, or even home, until muscle strength recovers. 
11. Outcome and prognosis 
11.1 Mortality 
Patients in myasthenic crisis have an excellent outcome if respiratory support can be 
provided adequately and in time. The prognosis of myasthenic crisis has substantially 
improved. During the early 1960s, respiratory care of these patients was transitioned from 
negative external pressure ventilation to positive pressure ventilation in an ICU. The 
mortality rate during hospitalization has decreased from 42% in the early 1960s to 6% by the 
late 1970s, between 3% and 10% in the early 1980s, and less than 3% in the 1990s. The 
median age at death also increased (Cohen and Younger, 1981). The rate of mortality has 
continued to decline after 1990, presumably because of improvements in respiratory care 
and availability of treatment options including IVIG and plasma exchange (Alshekhlee et al., 
2009). Based on the data in the US from 2000 through 2005, the overall in-hospital mortality 
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rate in patients with MG was 2.2%, being higher in patients with crisis (4.47%) (Alshekhlee 
et al., 2009). Older age and respiratory failure were the predictors of death, with adjusted 
odds ratios of 9.28 and 3.58, respectively (Alshekhlee et al., 2009). In that cohort, 
significantly higher occurrence of cardiac complications, sepsis, and deep vein thrombosis 
was observed among patients with crisis; however, none of these complications were 
independent predictors of death (Alshekhlee et al., 2009).  
11.2 Duration of mechanical ventilation and prognosis 
Prior reports indicated a median duration of intubation of 13 days or ICU stay of 14 days 
(Murthy et al., 2005; Tether, 1955). A recent study noted a shorter median length of hospital 
stay of 6 days. However, this duration was 17 days for myasthenic patients who underwent 
endotracheal intubation (Alshekhlee et al., 2009). Duration of intubation is an important 
predictor of functional outcome after crisis. About 25% of patients are extubated on hospital 
day 7, 50% by hospital day 13, and 75% by hospital day 31. Eighteen percent of patients will 
require discharge to a rehabilitation center (Alshekhlee et al., 2009). In a retrospective study 
of 73 episodes of crisis, risk factors for prolonged intubation include patient age over 50 
years, preintubation serum bicarbonate levels above 30 mg/dL, and highest VC of less than 
25 mL/kg during the first week of intubation (Thomas et al., 1997). The risk of prolonged 
intubation (i.e., >2 weeks) was 0% in patients with none of these risk factors, 20% in those 
with one risk factor, 50% in those with two risk factors, and 90% in those with three risk 
factors (Thomas et al., 1997). In another study, 77% of patients intubated for more than 2 
weeks had functional dependence at discharge compared with 36% of patients intubated for 
less than 2 weeks. 
 
1. Referred for intensive care. 
2. Initial step is stabilization of the airway 
3. Adequate oxygenation and ventilation.  
4. Airway protection if bulbar dysfunction to prevent aspiration. 
5. NIPPV if no contraindications. 
6. Monitor vital signs and repeated measurements of muscle strength 
(VC, PImax, SNIP, PEmax, peak cough flow…).  
7. 20/30/40 rule to guide intubation ( symptoms and signs more important). 
8. Elective rather than emergency intubation. 
9. Recommended initial ventilator settings: tidal volume 10 mL/kg, PS 5-15 
cm H2O and PEEP 5-15 cm H2O, peak airway pressure < 40 cm H2O   
10. Aggressive chest physiotherapy and airway clearance. 
11. Evaluation for weaning when muscular strength is objectively improved. 
12. Identify readiness for extubation by spontaneous breathing trials  
(T-piece, PS, automatic tube compensation...). 
13. Close monitoring and airway toilet after extubation. Tracheostomy is 
generally not needed. 
Table 2. Summary of respiratory care for myasthenic crisis 
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Myasthenic crisis is a rare but potentially life-threatening medical emergency and the 
diagnosis should be clinically suspected. The muscles involved and the degree of weakness 
vary from patient to patient, and respiratory care of these patients presents a challenge for 
the critical care practioners. Although no single factor determines the need for respiratory 
support, all patients with questionable respiratory status should be admitted to the ICU. 
Certain tests of respiratory muscle strength may help to identify impending respiratory 
failure and allow elective rather than emergent intubation. When treated aggressively 
adequately, patients generally have good outcomes in current practice. Successful 
management of patients not only involves the pharmacological aspect but a major part is 
mechanical ventilation. There is a clear need for formal randomized controlled trial of 
NIPPV in these patients as it seems to be a promising approach. Patient selection and close 
monitoring, however, remain important for successful application of NIPPV in myasthenic 
crisis. Because management of crisis includes treatment of the underlying MG, it is apparent 
that there is an urgent need for cooperation between specialist chest physicians, neurologists 
and respiratory therapists to optimize the care of this particular population of patients. 
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